Gyre Therapeutics, Inc. GYRE

GYRE Company Overview

Gyre Therapeutics, Inc. (NASDAQ: GYRE) is a biopharmaceutical company focused on the development and commercialization of therapies for organ fibrosis and inflammatory diseases. The company operates primarily in the healthcare and biotechnology sectors, with an emphasis on chronic liver, lung, and kidney diseases. Gyre’s core commercial and development activities are centered around anti-fibrotic therapeutics, particularly in the Chinese market, while also advancing pipeline assets targeting metabolic dysfunction-associated steatohepatitis (MASH), idiopathic pulmonary fibrosis (IPF), and related conditions.

The company evolved from a reverse merger involving Catalyst Biosciences, Inc. and entities affiliated with Gyre Pharmaceuticals. Through this transaction, Gyre Therapeutics acquired interests tied to China-based pharmaceutical operations and expanded its focus toward fibrosis-related drug development and commercialization. A central strategic asset is pirfenidone, an anti-fibrotic compound marketed in China for IPF through affiliated operations. Gyre positions itself through established commercialization infrastructure in China, access to fibrosis-focused intellectual property and development programs, and integration between clinical development and regional pharmaceutical distribution capabilities.